Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The document explains the causes, types, diagnosis, and treatments of hair loss, and its psychological impact, especially on women.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

This review discusses telogen effluvium, including its causes, symptoms, diagnostic methods, and treatment strategies, without presenting new clinical findings.

This study found that low dose methotrexate did not increase hair loss in rheumatoid arthritis patients compared to healthy controls, and many patients even showed a reduction in hair fall over the short term.

This chapter reviews types and causes of hair loss in children and suggests a diagnostic approach for identifying and treating this condition, but it reports no new clinical results.

This review discusses the pathophysiology of alopecia areata, highlighting the role of CD8 cytotoxic T cells and the upregulation of JAK signaling pathways; it reports no new experimental results.

In this study, oral spermidine supplementation was found to significantly prolong the hair follicle anagen phase and reduce hair loss, with effects persisting three months after treatment in healthy participants, suggesting potential therapeutic benefits for hair loss conditions.

In this study, the use of Selencin, both in tablet and peptide lotion form, over two months showed significant improvements in reducing hair loss and restoring hair structure and volume in patients with diffuse alopecia, with effects persisting up to four months after treatment.

This article describes a clinical case of a 67-year-old patient with telogen effluvium treated with a supplement containing amino acids, vitamin E, iron, and Serenoa repens, but reports no new clinical findings.

This paper reviews the differential diagnoses and diagnostic tests to distinguish alopecia areata from other types of hair loss, without providing new clinical findings.

Understanding hair structure and growth is key for diagnosing hair diseases accurately.

This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.

This article reviews recent advancements in understanding and treating androgenetic alopecia, focusing on new genetic insights, stem cell roles, and diagnostic tools, without reporting new clinical results.

This article reviews current knowledge on the causes, diagnosis, and medical treatments for androgenetic alopecia, particularly in men, and reports no new findings.

A vitamin and mineral supplement significantly reduced hair shedding in Brazilian women with telogen effluvium.

This descriptive abstract provides information about a continuing medical education activity for physicians, designating 1.5 credits for participation, but reports no new research findings.

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

In this case series, researchers observed androgenetic alopecia in 20 prepubertal children with a strong genetic predisposition, despite the condition typically not occurring before puberty.

In this study, patients receiving adipose-derived stromal vascular cell transplantation for alopecia areata experienced significant hair regeneration, increased growth, and improved hair quality after 3 and 6 months, indicating potential efficacy of this stem cell-based therapy for hair loss.

In this study, patients with androgenetic alopecia treated with platelet-rich plasma showed increased hair density and improved hair quality over six months, with no notable adverse effects, indicating that PRP may be an effective treatment option for this condition.

Dr. Vera H. Price's 1979 work emphasizes the importance of accurate diagnosis and personalized treatment for hair loss.

This study suggests that observing the acute telogen effluvium triad—frontal fringe, temporal recess, and occipital fringe—can aid in diagnosing telogen effluvium during resolution phases, despite challenges like negative pull tests.

This study found that PRP therapy was effective and safe for treating androgenic alopecia, promoting 30% hair growth and showing antimicrobial activity against certain bacteria in affected patients.

This review discusses various non-invasive methods for diagnosing alopecia areata, highlighting that trichoscopy signs like short vellus hairs and yellow dots are sensitive indicators of the condition, while advanced imaging techniques provide valuable information on hair follicle status and scalp inflammation.

This article discusses various causes and prevention methods for male pattern baldness but reports no new research findings.

This article reviews anagen effluvium, a type of non-scarring alopecia that affects both men and women, often induced by chemotherapy or radiation, and discusses diagnostic approaches but reports no new clinical findings.

In this clinical study, the researchers found that a standardized wheat polar lipid complex, in both oil and powder form, significantly reduced hair shedding and improved hair growth in 99 women with acute telogen effluvium over 56 to 84 days.

This study found that in patients with alopecia areata, trichoscopy was a valuable tool for monitoring disease activity, severity, and therapeutic response, showing changes in trichoscopic markers that preceded improvements observed in the hair pull test.

This study reports that the prevalence of female pattern hair loss increases with age, affecting 12% of women by age 29, 25% by age 50, and 41% to 50% by age 70 and older, with risk factors including genetics and certain endocrinological conditions.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.